mRNA-LNP Approach Reprograms Immune Cells into CAR NK Cells Inside the Body
Researchers describe using lipid nanoparticles to deliver mRNA that temporarily turns native immune cells into chimeric antigen receptor natural killer cells. This strategy could make CAR cell therapy less expensive and easier to control than extracting and engineering a patient's cells. The work is an early technology demonstration rather than an established clinical treatment.
The approach relies on lipid nanoparticles carrying messenger RNA into cells. After uptake, the RNA is translated into a receptor protein for only a few days before it degrades, making the effect transient rather than permanent. This places it between conventional gene therapy and a small-molecule medicine in duration.
CAR T therapy requires collecting a patient’s cells, modifying them, expanding them, and reinfusing them, which is costly and complex. CAR NK cells may offer an advantage against diseased T cells because they avoid the self-killing problem seen when CAR T cells target T-cell proteins. The reported work is an early demonstration, not an established treatment.
If the technology matures, patients who need CAR cell therapy could benefit from simpler, potentially less expensive treatment that does not require removing and engineering their own cells. Clinicians and manufacturers may gain a more controllable option because the reprogramming is temporary. However, early demonstrations often do not translate quickly, and access, safety, and durability would need extensive testing before any broad societal effect could be claimed.